The difference between Obinutuzumab and Rituximab

Obinutuzumab, which is marketed in China, is sold under the trade name of Garova, while Rituximab is sold under the trade name of Rituximab. Both drugs are prescription drugs and have entered the scope of Class B medical insurance.

Otuzumab is an intravenous drug used to treat certain types of cancer or slow its progression, often in combination with other treatments, such as: Chronic lymphocytic leukemia,This is the most common form of leukemia in adults. It first affects B lymphocytes (a type of white blood cell) in the bone marrow; follicular lymphoma, a cancer of the lymphatic system caused by abnormal B lymphocytes. Rituximab belongs to a class of drugs called monoclonal antibodies. It is used to treat non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and works by killing cancer cells. Certain injectable formulations of rituximab are also used to treat rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris by blocking the activity of parts of the immune system that can damage joints, veins, and other blood vessels.

Specifications1000mg (40ml) * 1 bottle Otuzumab The price of the original drug in China may be around more than 9,000 yuan. It is a strictly controlled drug and must be used by doctors and medical staff. The Turkish version of Otuzumab Specifications priced at more than RMB 10,000 per box of 1000 mg/40 ml (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold at home and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yade.